Applicability of EU(7)-PIM criteria in cross-national studies in European countries

Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015–November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8–21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4–48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017–2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.

[1]  J. Hanlon,et al.  American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults , 2019, Journal of the American Geriatrics Society.

[2]  H. Brenner,et al.  The associations of geriatric syndromes and other patient characteristics with the current and future use of potentially inappropriate medications in a large cohort study , 2018, European Journal of Clinical Pharmacology.

[3]  M. Elseviers,et al.  European repository of explicit criteria of potentially inappropriate medications in old age , 2018, Geriatrics & gerontology international.

[4]  E. Şahi̇n,et al.  A POPULATION-BASED STUDY: THE APPROPRIATENESS OF DRUG USE IN THE ELDERLY ACCORDING TO BEERS CRITERIA , 2018 .

[5]  Goran Katić.  Statistical Office of the Republic of Serbia SYSTEM OF COMPOSITE INDICATORS OF THE ECONOMIC ACTIVITY OF SERBIA (VIPAS) IN SHORT TERM FORECASTING OF GDP , 2018 .

[6]  D. Toprak,et al.  FREQUENCY OF POLYPHARMACY AND USE OF POTENTIALLY INAPPROPRIATE MEDICATIONS IN THE ELDERLY , 2017 .

[7]  M. Izquierdo,et al.  Impact of hospitalization in an acute geriatric unit on polypharmacy and potentially inappropriate prescriptions: A retrospective study , 2017, Geriatrics & gerontology international.

[8]  J. Polli,et al.  Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey , 2017, Annals of the New York Academy of Sciences.

[9]  I. Mucalo,et al.  Potentially inappropriate medicines in elderly hospitalised patients according to the EU(7)-PIM list, STOPP version 2 criteria and comprehensive protocol , 2017, European Journal of Clinical Pharmacology.

[10]  G. Szalai,et al.  Medication use and risk of falls among nursing home residents: a retrospective cohort study , 2017, International Journal of Clinical Pharmacy.

[11]  V. Briedis,et al.  The use of potentially inappropriate medications among the Lithuanian elderly according to Beers and EU(7)‐PIM list – a nationwide cross‐sectional study on reimbursement claims data , 2017, Journal of clinical pharmacy and therapeutics.

[12]  I. Scott,et al.  Review of structured guides for deprescribing , 2016, European journal of hospital pharmacy. Science and practice.

[13]  T. Fahey,et al.  Impact of Potentially Inappropriate Prescribing on Adverse Drug Events, Health Related Quality of Life and Emergency Hospital Attendance in Older People Attending General Practice: A Prospective Cohort Study , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[14]  K. Johnell,et al.  Prevalence of Potentially Inappropriate Medication Use in Older Adults Living in Nursing Homes: A Systematic Review. , 2016, Journal of the American Medical Directors Association.

[15]  T. Stürmer,et al.  Trends in Prevalence and Determinants of Potentially Inappropriate Prescribing in the United States: 2007 to 2012 , 2016, Journal of the American Geriatrics Society.

[16]  Joshua D. Brown,et al.  Predictive Validity of the Beers and Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States , 2016, Journal of the American Geriatrics Society.

[17]  C. Dubeau,et al.  How to Use the American Geriatrics Society 2015 Beers Criteria—A Guide for Patients, Clinicians, Health Systems, and Payors , 2015, Journal of the American Geriatrics Society.

[18]  J. Long,et al.  A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. , 2015, British journal of clinical pharmacology.

[19]  Mary Jordan Samuel.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2015, Journal of the American Geriatrics Society.

[20]  M. Elseviers,et al.  Availability and actual use in the Belgian market of potentially inappropriate medications (PIMs) from the EU(7)-PIM list , 2016, European Journal of Clinical Pharmacology.

[21]  E. Mehuys,et al.  Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review , 2015, European Journal of Clinical Pharmacology.

[22]  Tom Fahey,et al.  Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study , 2015, BMJ Open.

[23]  G. Meyer,et al.  The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries , 2015, European Journal of Clinical Pharmacology.

[24]  A. Klovning,et al.  The Norwegian General Practice – Nursing Home criteria (NORGEP-NH) for potentially inappropriate medication use: A web-based Delphi study , 2015, Scandinavian journal of primary health care.

[25]  Paul Gallagher,et al.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 , 2014, Age and ageing.

[26]  Canary Wharf,et al.  European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure , 2015 .

[27]  G. Onder,et al.  Potentially inappropriate drug use among hospitalised older adults: results from the CRIME study. , 2014, Age and ageing.

[28]  C. Teljeur,et al.  Potentially Inappropriate Prescribing and Vulnerability and Hospitalization in Older Community-Dwelling Patients , 2014, The Annals of pharmacotherapy.

[29]  N. Peel,et al.  Potentially Inappropriate Prescribing in Older Patients Discharged From Acute Care Hospitals to Residential Aged Care Facilities , 2014, The Annals of pharmacotherapy.

[30]  B. Miljković,et al.  Potentially Inappropriate Prescribing in Older Primary Care Patients , 2014, PloS one.

[31]  J. Baeyens,et al.  Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals , 2011, European Journal of Clinical Pharmacology.

[32]  Sven Schmiedl,et al.  Potentially inappropriate medications in the elderly: the PRISCUS list. , 2010, Deutsches Arzteblatt international.

[33]  Olav Spigset,et al.  The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients , 2009, Scandinavian journal of primary health care.

[34]  M. Pahor,et al.  Impact of inappropriate drug use on physical performance among a frail elderly population living in the community , 2007, European Journal of Clinical Pharmacology.

[35]  L. Merle,et al.  Potentially inappropriate medications in the elderly: a French consensus panel list , 2007, European Journal of Clinical Pharmacology.

[36]  Cordula Wagner,et al.  Potentially inappropriate medication use among elderly home care patients in Europe. , 2005, JAMA.

[37]  Lucie Baillargeon,et al.  Potentially inappropriate prescriptions for older patients in long-term care , 2004, BMC geriatrics.

[38]  R. Tamblyn,et al.  Defining inappropriate practices in prescribing for elderly people: a national consensus panel. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[39]  D B Reuben,et al.  Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. , 1991, Archives of internal medicine.